Cargando…

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model

Cognitive impairment is a common non-motor complication of Parkinson’s disease (PD). Glucocerebrosidase gene (GBA1) variants are found in 10–15% of PD cases and are numerically the most important risk factor for PD and dementia with Lewy bodies. Accumulation of α-synuclein and tau pathology is thoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shi Yu, Taanman, Jan-Willem, Gegg, Matthew, Schapira, Anthony H V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	General Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307316/ https://www.ncbi.nlm.nih.gov/pubmed/35179198 http://dx.doi.org/10.1093/hmg/ddac038

Ejemplares similares

Ambroxol effects in glucocerebrosidase and α‐synuclein transgenic mice
por: Migdalska‐Richards, Anna, et al.
Publicado: (2016)

No evidence for substrate accumulation in Parkinson brains with GBA mutations
por: Gegg, Matthew E., et al.
Publicado: (2015)

Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation
por: Yang, Shi-yu, et al.
Publicado: (2020)

The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines
por: Smith, Laura J, et al.
Publicado: (2022)

Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons
por: Gegg, Matthew E, et al.
Publicado: (2020)

α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism
por: Yun, Seung Pil, et al.
Publicado: (2018)

Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models
por: Sanchez-Martinez, Alvaro, et al.
Publicado: (2016)

Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
por: Galvagnion, Céline, et al.
Publicado: (2022)

Effects of ambroxol on the autophagy-lysosome pathway and mitochondria in primary cortical neurons
por: Magalhaes, J., et al.
Publicado: (2018)

L444P Gba1 mutation increases formation and spread of α-synuclein deposits in mice injected with mouse α-synuclein pre-formed fibrils
por: Migdalska‐Richards, Anna, et al.
Publicado: (2020)

DNA Methylation of α-Synuclein Intron 1 Is Significantly Decreased in the Frontal Cortex of Parkinson’s Individuals with GBA1 Mutations
por: Smith, Adam R., et al.
Publicado: (2023)

A Human Neural Crest Stem Cell-Derived Dopaminergic Neuronal Model Recapitulates Biochemical Abnormalities in GBA1 Mutation Carriers
por: Yang, Shi-Yu, et al.
Publicado: (2017)

ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons
por: Fernandes, Hugo J.R., et al.
Publicado: (2016)

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
por: McNeill, Alisdair, et al.
Publicado: (2014)

Impact of Gba2 on neuronopathic Gaucher’s disease and α-synuclein accumulation in medaka (Oryzias latipes)
por: Nakanishi, Etsuro, et al.
Publicado: (2021)

Silencing of PINK1 Expression Affects Mitochondrial DNA and Oxidative Phosphorylation in DOPAMINERGIC Cells
por: Gegg, Matthew E., et al.
Publicado: (2009)

GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models
por: Morén, Constanza, et al.
Publicado: (2019)

The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
por: Migdalska-Richards, Anna, et al.
Publicado: (2017)

Posterior Cortical Atrophy phenotype in a GBA N370S mutation carrier: a case report
por: Picillo, Marina, et al.
Publicado: (2021)

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review
por: Behl, Tapan, et al.
Publicado: (2021)

GBA Variants and Parkinson Disease: Mechanisms and Treatments
por: Smith, Laura, et al.
Publicado: (2022)

The Role of Cholesterol in α‐Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease
por: García‐Sanz, Patricia, et al.
Publicado: (2020)

Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson’s disease
por: Kumar, Manoj, et al.
Publicado: (2023)

Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate
por: Migdalska‐Richards, Anna, et al.
Publicado: (2017)

Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus
por: Devine, Michael J., et al.
Publicado: (2011)

Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression
por: Ridova, Nevenka, et al.
Publicado: (2022)

Endoplasmic reticulum and lysosomal Ca(2+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts
por: Kilpatrick, Bethan S., et al.
Publicado: (2016)

The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models
por: Polinski, Nicole K., et al.
Publicado: (2022)

Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
por: Miller, Rebecca L., et al.
Publicado: (2022)

GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
por: Brockmann, Kathrin
Publicado: (2020)

α-Synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells: an in vitro proof of concept study
por: Hurley, Michael J, et al.
Publicado: (2023)

D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model
por: Kim, Donghoon, et al.
Publicado: (2018)

Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers
por: Menozzi, Elisa, et al.
Publicado: (2021)

Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson’s Disease
por: Grigor’eva, Elena V., et al.
Publicado: (2023)

Pramipexole Reduces Phosphorylation of α-Synuclein at Serine-129
por: Chau, Kai-Yin, et al.
Publicado: (2013)

Visual short-term memory deficits associated with GBA mutation and Parkinson’s disease
por: Zokaei, Nahid, et al.
Publicado: (2014)

Ambroxol Hydrochloride Combined with Fluconazole Reverses the Resistance of Candida albicans to Fluconazole
por: Li, Xiuyun, et al.
Publicado: (2017)

Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease
por: Mullin, Stephen, et al.
Publicado: (2020)

A LON-ClpP Proteolytic Axis Degrades Complex I to Extinguish ROS Production in Depolarized Mitochondria
por: Pryde, Kenneth Robert, et al.
Publicado: (2016)

Evolution and clustering of prodromal parkinsonian features in GBA1 carriers
por: Mullin, Stephen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jprslmuq5uuks42eqioocd5je7